Kobe, Japan- August 2024- Sysmex Corporation announces that it has expanded its strategic Alliance Agreement with QIAGEN N.V. to deepen its collaboration in genetic testing, including research and development, production, clinical development, and sales-marketing.
Sysmex and QIAGEN have built a successful partnership since the initial collaboration back in 2013 and agreed to expand it to include a strategic alliance for companion diagnostics in 2021. As part of the newly expanded collaboration, both companies will further combine their respective products and strengths in genetic testing to deliver high-value products to their global customers.
Sysmex will implement QIAGEN’s assay to be used for clinical trials that QIAGEN provides to pharmaceutical companies and research institutions at Sysmex’s global network laboratories and support QIAGEN’s global services.
For more than 50 years, Sysmex has enhanced its global presence within the in vitro diagnostics field by evolving its genetic testing portfolio. One of the ways is by bringing personalized medicine to patients and healthcare professionals through product development using liquid biopsy technology. Sysmex has built a global sales and services network that utilizes its world-class laboratories in Japan and the United States. Sysmex intends to accelerate the creation of high-value testing and develop diagnostic technologies further.
Also Read: AbbVie Completes Acquisition of Cerevel Therapeutics
QIAGEN is a pioneer in precision medicine and the leader in collaborating with pharmaceutical and biotechnology companies to develop companion diagnostics. These can detect genetic abnormalities to provide insights that guide clinical decision-making about treatments.
